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INTRODUCTION
Heteroaromatic compounds have  attracted  considerable  attention  in  the  design  of  biologically
active molecules and advanced organic materials.1 Hence, a practical method  for  the  preparation
of such compounds is of great interest in synthetic organic chemistry. Pyrazole and its derivatives,
a class of well known nitrogen containing heterocyclic compounds, occupy an  important  position
in  medicinal  and  pesticide  chemistry  with  having  a  wide  range   of   bioactivities      such   as
antimicrobial,2                                                      anticancer,3                                                      anti-
inflammatory,4 antidepressant,5anticonvulsant,5,6 antihyperglycemic,7  antipyretic,8 antibacterial,  9
antifungal activities,10 CNS regulants,11 and  selective  enzyme  inhibitory  activities12.  It  has  been
found that these compounds have hypoglycemic activity,  and  are  also  known  as  inhibitors  and
deactivators of liver alcohol dehydrogenase and oxidoreductases.13 It has been shown in vivo  that
some of the pyrazole derivatives have appreciable antihypertensive  activity.14  These  compounds
also exhibit properties  such as cannabinoid hCB1 and hCB2 receptor, , inhibitors of  p38  Kinase,
CB1 receptor antagonists15,16 .The biological activity  of  certain  pyrazole  derivatives  have  been
discussed here .
The 1-phenylpyrazole motif is present in several drug candidates for treatment of various  diseases
such  as  cyclooxygenase-2  (Cox-2)  inhibitors,  IL-1  synthesis  inhibitors,   and   protein   kinase
inhibitors etc.  Similarly a few of the 1,5-diarylpyrazole derivatives  have  been  shown  to  exhibit
non-nucleoside HIV-1 reverse transcriptase inhibitory activities  along with Cox-2 inhibitor.17
Several   substituted   pyrazolo[3,4-d]pyrimidine   derivatives   have   xanthine   oxidase   inhibitor
activity18, like allopurinol which was first synthesized by Robins in 1956 and is  still  the  drug  for
the treatment of hyperuricemia and gouty arthritic disease.19
The  pyrazolo[1,5-a]pyrimidines  e.g.  Indiplon  (1a)  and  Zaleplon  (1b)  and  the  N,N-dialkyl-2-
phenylacetamidoimidazo[1,2-a]pyridines e.g. Zolpidem (2a) and Alpidem (2b) are  also  used  for
the treatment of anxiety sleep disorders, convulsions, and memory deficits.20
Urea  derivatives  of  5-aminopyrazoles  have  recently  been   reported   as   potent   inhibitors   of
P38 kinase, TNF-? production, and cholesterol acyltransferase.21
Curcuminoid pyrazoles are used as new therapeutic agents  in  inflammatory  bowel  disease.  The
activity of the curcuminoid pyrazoles covers domains such as anti-inflammatory (5-lipooxygenase
and cyclooxygenase inhibitors), antitumoral (anti-angiogenic) and drugs for  the  treatment  of  the
Alzheimer disease.22
The importance of pyrazole exploited from the appearance of some pesticides in the market in  the
name  of  fripronil  (Colliotet   al.,   1992)   (3),   topramezon   (BASF,   2006)(4),   pyraelostrobin
(BASF,2001)(5) etc.23 
The pyrazole ring is a constituent of  a  variety  of  natural  and  synthetic  products.  Examples  of
pyrazole ring containing natural products are (S)-3-pyrazolylalanine(6), pyrazomycine(7), and 4,5-
dihydro-3-phenyl-6H-pyrrolo[1,2–b]pyrazole      (8),      while       lonazolac       (9),       fezolamin
(10),difenamizole (11), and mepirizole(12) are examples of biologically active synthetic  pyrazole
derivatives .
Pyrazoles  are  usually  prepared  by  condensation  between  a  hydrazine  derivative  and   a   1,3-
dicarbonyl compound or by 1,3-dipolar cycloaddition of diazoalkanes or nitrile  imines  to  olefins
or  acetylenes.24  Here,  in  this  report  our  approach  towards  the  synthesis  of  some  polycyclic
pyrazole compounds by the Diels-Alder reaction of furo[3,4-c]pyrazole and several dienophiles  is
disclosed.  As  furo[3,4-c]pyrazole  is  unknown  till  now,  we  want  to  focus  our  study  for  the
synthesis  of  furo[3,4-c]pyrazole.  Our  approach  towards  furo[3,4-c]pyrazole    and   subsequent
[4+2]cycloaddition reaction is outlined in Scheme 1.
Scheme 1
RESULT AND DISCUSSION
The most important methods for preparing  this  class  of  heterocycles  are  the  reaction  between
hydrazines with ?-difunctional compounds25  and 1, 3-dipolar cycloadditions of diazo  compounds
onto triple bonds26. The former process, considered to be the best  method  for  the  preparation  of
pyrazoles,   involves   the   double   condensation   of   1,   3-diketones   with    hydrazine    or    its
derivatives.27 This method has a wide scope not only because of the  readily  availability  of  1,  3-
diketones but also because one carbonyl of the diketone starting material  can  be  replaced  by  an
acetal, a hemiacetal, a chlorovinyl group, dihalides, etc.25
The   conventional   method   of   preparation   of   pyrazole   or   pyrazole   derivatives   involving
condensation of 1,3-diketones with phenyl hydrazine or its derivatives require long time  (7-8 hrs)
with lower yield.  And  it  requires  organic  toxic  solvent  as  a  reaction  medium.  But  we  have
developed an efficient method of synthesis pyrazole type of compound by solvent free reaction  of
1,3-diketone with phenyl hydrazine under  microwave irradiation in short time  (8-10  min).  Thus
the reaction of 1,3- dicarbonyl compound with  phenyl  hydrazine  in  silica  gel  G  support  under
microwave  irradiation  for  8-10  mins  give  pyrazolone  (14)  in  excellent   yield.14b   shows   a
characteristic absorption peak at 1709 cm-1 (C=O stretching  ).Reaction  of  14  with  phosphorous
oxychloride 80-900c result in the chlorination at C-5 position to form 5-chloro-pyrazole derivative
15 (Scheme 2). Formation of 15b  is evident from 1H NMR spectrum,  which  shows  signals  at  ?
7.77-7.17 (m) for 10 protons of phenyl ring and another singlet at 6.63 for the C4-H proton.
Scheme 2
Pyrazole  derivative  15  was  selectively  formylated   at   C-4   using   Vilsmeier-Haack   reaction
condition (Scheme 3). Formation of 16a was confirmed from IR  as  well  as  NMR  spectroscopy.
16a shows characteristic IR absorption band at 1676.73 cm-1 (C=O stretching) and a sharp  singlet
at ? 9.92 for CHO, at ? 2.491 for –CH3.  Similarly IR spectrum of 16b  show  a  strong  absorption
band at 1683cm-1 (C=O stretching), 1H NMR spectrum, which  shows  signals  at  ?  7.20-7.78  for
aromatic protons .Reactions of 16a with NaBH4 result in the reduction of aldehyde group   alcohol
17 (Scheme 4).
Scheme -3
Scheme-4
In order to  introduce  a  thiophenyl  group,  we  chlorinated  the  alcohol  by  oxalyl  chloride  and
nucleophilically substituted the chloro group by thiophenolate ion in-situ without isolation  of  the
chloro compound 18 (Scheme 5).
Scheme-5
CONCLUSION
The present work embodies the synthesis of pyrazole derivative in  solid  phase  under  microwave
irradiation of ?-dicarbonyl compounds with phenylhydrazine within a very short time  (8-10  min)
in good yield. The transformation of the pyrazolone to the precursor for Pummerer reaction which
may lead to furo[3,4-Ic]pyrazole is an ongoing work  in our laboratory and will be reported in  due
course.
EXPERIMENTAL SECTION
3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (14a)
To a mixture of ethyleacetoacetate (3.84mmol, 0.49ml) and phenyl hydrazine (3.84mmol, 0.38ml)
a drop of concentrated H2SO4 was added. To this mixture 2gm of silica  gel  G  was  added  and  it
was grinded thoroughly. The mixture was heated in a microwave for  8-10  minutes.  Then  it  was
washed with CH2Cl2 repeatedly and the extract was dried over anhydrous Na2SO4 and  the  solvent
was removed under vacuum yielding yellow solid which  was  washed  with  petroleum  ether  and
2% polar solution to give the pure product as light yellow crystalline solid.
Yield-69%
 1, 3-diphenyl-1H-pyrazol-5(4H)-one (14b)
1,3-diphenyl-1H-pyrazol-5(4H)-one  (2b)  was  obtained  by  the  condensation  of   ethylebenzoyl
acetate (500mg, 2.6011mmol)  and  phenyl  hydrazine  (0.257ml,  2.6011ml)  following  the  same
procedure as described for compound 2a in the form of yellow crystalline solid.
Yield-85.16%
 IR (KBr)-1709.61cm-1
5-chloro-3-methyl-1-phenyl-1H-pyrazole (15a)
A mixture of 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one  (3.7gm,  21.264mmol)  and  phosphorous
oxychloride (7.93ml, 85.056mmol)  was  stirred  under  nitrogen  atmosphere  at  80-900  for  7hrs.
Then the reaction mixture was cooled to room  temperature  and  poured  into  ice-cold  water  and
neutralized by careful addition of saturated solution of NaHCO3  in  small  portions  with  stirring.
The  resulting  mixture  was  then  extracted  with  CH2Cl2  repeatedly.  The  combined  layer  was
washed with brine solution and dried over  anhydrous  Na2SO4  and  the  organic  layer  was  dried
under vacuum. The crude compound was then purified by column chromatography.
Yield-65.6%
5-chloro-1, 3-diphenyl-1H-pyrazole (15b)
1,3-diphenyl-1H-pyrazol-5(4H)-one (3gm,12.962mmol) was taken with phosphorous  oxychloride
(POCl3 ,4.83ml,51.85mmol) and proceeding as for compound 3a  we  get  5-chloro-1,  3-diphenyl-
1H-pyrazole.
Yield-84.78% 1H NMR (300MHz) ? 7.77-7.17(m, 10H, ArH), 6.63(s, 1H, CH),
5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (16a)
Dimethylformamide (DMF) (5ml) and  phosphorous  oxychloride  (4.728ml,  0.515mmol)     were
mixed under ice cold condition at nitrogen atmosphere.  Then  it  was  allowed  to  come  to  room
temperature and  stirred  for  30  minutes.  5-chloro-3-methyl-1-phenyl-1H-pyrazole  (2gm,  10.38
mmol) dissolved in DMF was  added  to  it  and  then  heated  at  80-900  for  8hrs  under  nitrogen
atmosphere. Then it was cooled to room temperature. The reaction mixture was poured to ice cold
water followed by neutralization with saturated solution of NaHCO3. Then  the  resulting  mixture
was extracted with CH2Cl2 repeatedly and the organic layer was dried over anhydrous Na2SO4 and
concentrated  under  reduced  pressure.  The  black  crude  compound  was   purified   by   column
chromatography   yielding   5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde     as   white
crystalline solid.
Yield-78%
IR (KBr)-1676cm-1 ,1H NMR ? 7.19-7.82(Phenyl H), 9.92(Aldehyde H),2.4(-CH3),
5-chloro-1,3-diphenyl-1H-pyrazole-4-carbaldehyde (16b)
 5-chloro-1,3-diphenyl-1H-pyrazole (3b) was taken and  white  crystals  of  5-chloro-1,3-diphenyl-
1H-pyrazole-4-carbaldehyde was synthesized  following the procedure given for compound 16a.
Yield-71%
IR-1683.61cm-1
5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl) methanol (17)
To  a   stirred   solution   of   5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde   (1.8   gm,
8.163mmol) in ethanol  (5ml),  sodium  borohydride  (NaBH4)  was  added  gradually  in  ice  cold
condition. Then it was allowed to stir for 6-7 hours at room temperature. The reaction mixture was
then extracted with  CH2Cl2    and  washed  with  dilute  HCl.  The  organic  layer  was  dried  over
anhydrous Na2SO4 and concentrated under reduced pressure  to  get  (5-chloro-3-methyl-1-phenyl-
1H-pyrazol-4-yl) methanol as white solid.
Yield -63.31%
5-chloro-4-(chloromethyl)-3-methyl-1-phenyl-1H-pyrazole (18)
To a stirred solution of  (5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)  methanol(1.6g,7.19mmol)
in    benzene(10-12    ml)     was    added    1    drop    of    DMF    and    oxalyl    chloride    (1.376
ml,17.975mmol) under nitrogen atmosphere. Then the reaction mixture was heated at reflux for 2-
3 hrs. Then the solvent  was  removed  under  reduced  pressure  and  the  intermediate  compound
6 was subjected to next step immediately without further purification.
5-chloro-3-methyl-1-phenyl-4-((phenylthio)methyl)-1H-pyrazole(19)
To the above resulting gummy liquid 5ml of dry benzene was added. Then thiophenol  was  added
drop wise at 00. Then to this well stirred solution 0.5ml of pyridine was  added  and  stirred.  Then
the reaction mixture was allowed to come  at  room  temperature  and  stirred  for  2hrs.  Then  the
reaction mixture was poured in to water and extracted with CH2Cl2.The organic layer was  washed
with dil. HCl and dried over anhydrous  NaSO4.  Then  the  solvent  was  removed  under  reduced
pressure and the resulting mixture was purified by column chromatography.
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Fig. 1: IR spectra of 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one(14a)
Fig. 2: IR spectra of 1, 3-diphenyl-1H-pyrazol-5(4H)-one (14b)
Fig. 3: IR spectra of 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde(16a)
Fig.6: IR spectra of 5-chloro-1,3-diphenyl-1H-pyrazole-4-carbaldehyde (16b)
